Study of entinostat for pediatric sarcoma with PAX gene changes
Treatments studied
Part of Cancer clinical trials.
This trial tests an investigational drug called entinostat for children with a rare type of soft tissue sarcoma that has a specific gene change (PAX). The goal is to see if the drug can help shrink or control the tumor, either alone or combined with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is between 1 and 18 years old.
- Sarcoma has a PAX gene change (like PAX3-FOXO1 or PAX7-FOXO1).
- If taking the drug alone: standard treatment worked well (cancer shrank or disappeared).
- If taking the drug with other drugs: standard treatment didn't work well, or cancer came back or spread.
- Good overall health: able to do daily activities, blood counts are adequate, and life expectancy is at least 6 months.
- No prior stem cell or organ transplant, no active serious infection, and no recent participation in another drug trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
This Phase 2 trial tests pazopanib alone or together with pembrolizumab to slow or shrink metastatic soft-tissue sarcoma after prior chemotherapy. It may help some people by strengthening the anti-cancer effect compared with pazopanib by itself.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
This trial studies whether nivolumab (an immune therapy) plus entinostat (an epigenetic medicine) can help children and teens with high-risk cancers that have come back, worsened, or did not respond to prior treatment. It also looks at specific tumor “biomarkers” to group patients and guide how the study is run.
This trial uses lab-grown tumor samples from your child to test which chemotherapy drugs work best for their specific cancer. The goal is to find the most effective treatment by testing medicines on their tumor cells before giving them to your child.
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.